Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 100 citing articles:

Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26
Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein
Zhuocheng Yao, Lin Zhang, Yuange Duan, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106121-106121
Open Access | Times Cited: 10
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Ching‐Lin Hsieh, Sarah R. Leist, Emily Happy Miller, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster
Julien Favresse, Constant Gillot, Mélanie Closset, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Open Access | Times Cited: 7
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 83-83
Open Access | Times Cited: 6
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Chijioke Bennett, Wayne Woo, Mark Bloch, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 6, pp. 581-593
Open Access | Times Cited: 6
Insights into Omicron: Genomic Characterization and Inpatient Risk Assessment at Single Tertiary Hospital in Indonesia
Dewi Kartika Turbawaty, Dewi Komala, Basti Andriyoko
Journal of Multidisciplinary Healthcare (2025) Vol. Volume 18, pp. 71-81
Open Access
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice
Xiaoming Liang, Yuxia Yuan, Junbin Wang, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages
H. J. Yang, Xuemei He, Shi H, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
The trend of phylogenetic and epitope variations of SARS-CoV-2 Omicron sub-lineages in Iran
Mehdi Shabani, Ahmad Nejati, Jila Yavarian, et al.
Frontiers in Microbiology (2025) Vol. 15
Open Access
Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis
Durga Kulkarni, Bohee Lee, Nabihah Farhana Ismail, et al.
Journal of Global Health (2025) Vol. 15
Open Access
Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1502-1502
Open Access | Times Cited: 19
Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
Robert Flisiak, Dorota Zarębska‐Michaluk, Krystyna Dobrowolska, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5572-5572
Open Access | Times Cited: 16
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants
Tanmay Ghildiyal, Nishant Rai, Janhvi Mishra Rawat, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-19
Open Access | Times Cited: 5
Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination
Stefan Gravenstein, Frank DeVone, Oladayo A Oyebanji, et al.
EBioMedicine (2024) Vol. 105, pp. 105180-105180
Open Access | Times Cited: 5
Diversity of Omicron sublineages and clinical characteristics in hospitalized patients in the southernmost state of Brazil
Jaqueline Rhoden, Andressa Taíz Hoffmann, Janaína Franciele Stein, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination
Hakjun Hyun, Eliel Nham, Hye Seong, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Evolution and implications of SARS-CoV-2 variants in the post-pandemic era
Emery Manirambona, Olalekan John Okesanya, Noah Olabode Olaleke, et al.
Deleted Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 4
An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies
Lucia Spicuzza, Davide Campagna, Chiara Di Maria, et al.
AIMS Microbiology (2023) Vol. 9, Iss. 2, pp. 375-401
Open Access | Times Cited: 13
Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
Peter Halfmann, Ryuta Uraki, Makoto Kuroda, et al.
EBioMedicine (2023) Vol. 93, pp. 104677-104677
Open Access | Times Cited: 13
Vaccination, immunity, and the changing impact of COVID-19 on infant health
Florencia Torche, Jenna Nobles
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 11
Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact
Debayan Sil, Shreastha Gautam, Shubhi Saxena, et al.
Current Drug Targets (2024) Vol. 25, Iss. 8, pp. 517-525
Closed Access | Times Cited: 3
In vitro and in silico study of biosynthesized silver nanoparticles using Nigella sativa extract against SARS-CoV-2 and Candida albicans
Henda Daoudi, Abderrhmane Bouafia, Salah Eddine Laouini, et al.
Journal of Molecular Liquids (2024) Vol. 405, pp. 125059-125059
Open Access | Times Cited: 3
SARS-CoV CH.1.1 Variant: Genomic and Structural Insight
Liliana Bazzani, Elena Imperia, Fabio Scarpa, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 3, pp. 292-298
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top